KR20210071101A - Tor 키나제 억제자를 사용하는 암의 치료 - Google Patents

Tor 키나제 억제자를 사용하는 암의 치료 Download PDF

Info

Publication number
KR20210071101A
KR20210071101A KR1020217017407A KR20217017407A KR20210071101A KR 20210071101 A KR20210071101 A KR 20210071101A KR 1020217017407 A KR1020217017407 A KR 1020217017407A KR 20217017407 A KR20217017407 A KR 20217017407A KR 20210071101 A KR20210071101 A KR 20210071101A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
pyrazin
tor kinase
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217017407A
Other languages
English (en)
Korean (ko)
Inventor
슈이찬 주
크리스튼 메이 헤게
헤더 레이몬
릴리 로레인 웡
Original Assignee
시그날 파마소티칼 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그날 파마소티칼 엘엘씨 filed Critical 시그날 파마소티칼 엘엘씨
Publication of KR20210071101A publication Critical patent/KR20210071101A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217017407A 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료 Ceased KR20210071101A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US61/611,361 2012-03-15
US201261715323P 2012-10-18 2012-10-18
US61/715,323 2012-10-18
KR1020207016306A KR20200070416A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016306A Division KR20200070416A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Publications (1)

Publication Number Publication Date
KR20210071101A true KR20210071101A (ko) 2021-06-15

Family

ID=48014336

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207016306A Ceased KR20200070416A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
KR1020217017407A Ceased KR20210071101A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료
KR1020147028707A Active KR102122617B1 (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207016306A Ceased KR20200070416A (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147028707A Active KR102122617B1 (ko) 2012-03-15 2013-03-14 Tor 키나제 억제자를 사용하는 암의 치료

Country Status (21)

Country Link
US (1) US20130245026A1 (enExample)
EP (1) EP2825170B1 (enExample)
JP (3) JP2015510891A (enExample)
KR (3) KR20200070416A (enExample)
CN (2) CN104519885A (enExample)
AU (1) AU2013203153B2 (enExample)
BR (1) BR112014022703A2 (enExample)
CA (1) CA2866872A1 (enExample)
EA (1) EA028414B1 (enExample)
ES (1) ES2677874T3 (enExample)
IL (1) IL234602B (enExample)
MX (1) MX360878B (enExample)
MY (1) MY174022A (enExample)
NI (1) NI201400111A (enExample)
NZ (1) NZ628416A (enExample)
PH (1) PH12014502029A1 (enExample)
SG (1) SG11201405707XA (enExample)
TW (1) TWI583385B (enExample)
UA (1) UA114315C2 (enExample)
WO (1) WO2013138557A1 (enExample)
ZA (1) ZA201406706B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104519885A (zh) * 2012-03-15 2015-04-15 西格诺药品有限公司 用tor激酶抑制剂治疗癌症
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105188704B (zh) 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
KR102221029B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
PH12021552945B1 (en) 2013-04-17 2024-02-28 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
US20140314673A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EA037683B1 (ru) 2013-04-17 2021-04-29 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтические составы, способы, твердые формы и способы применения, относящиеся к 1-этил-7-(2-метил-6-(1h-1,2,4-триазол-3-ил)пиридин-3-ил)-3,4-дигидропиразино[2,3-b] пиразин-2(1h)-ону
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
UA115805C2 (uk) 2013-04-17 2017-12-26 Сігнал Фармасьютікалз, Елелсі Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
CN105407892B (zh) 2013-05-29 2019-05-07 西格诺药品有限公司 一种化合物的药物组合物、其固体形式及它们的使用方法
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CA2955009A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101504669B1 (ko) * 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
CN101679432B (zh) 2006-10-19 2015-04-22 西格诺药品有限公司 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
CN104519885A (zh) * 2012-03-15 2015-04-15 西格诺药品有限公司 用tor激酶抑制剂治疗癌症

Also Published As

Publication number Publication date
MX360878B (es) 2018-11-21
CA2866872A1 (en) 2013-09-19
IL234602A0 (en) 2014-11-30
WO2013138557A1 (en) 2013-09-19
PH12014502029B1 (en) 2014-11-24
EP2825170B1 (en) 2018-05-09
ZA201406706B (en) 2016-05-25
KR20140138927A (ko) 2014-12-04
AU2013203153A1 (en) 2013-10-03
IL234602B (en) 2020-05-31
TW201343168A (zh) 2013-11-01
NI201400111A (es) 2015-01-15
KR102122617B1 (ko) 2020-06-12
TWI583385B (zh) 2017-05-21
MY174022A (en) 2020-03-04
SG11201405707XA (en) 2014-10-30
UA114315C2 (uk) 2017-05-25
EA028414B1 (ru) 2017-11-30
AU2013203153B2 (en) 2015-09-03
KR20200070416A (ko) 2020-06-17
EP2825170A1 (en) 2015-01-21
JP2015510891A (ja) 2015-04-13
CN104519885A (zh) 2015-04-15
JP2019108368A (ja) 2019-07-04
MX2014011077A (es) 2014-10-14
PH12014502029A1 (en) 2014-11-24
HK1201750A1 (en) 2015-09-11
ES2677874T3 (es) 2018-08-07
EA201491699A1 (ru) 2015-02-27
CN108992446A (zh) 2018-12-14
BR112014022703A2 (pt) 2021-05-04
NZ628416A (en) 2016-04-29
US20130245026A1 (en) 2013-09-19
JP2021102637A (ja) 2021-07-15

Similar Documents

Publication Publication Date Title
US20230338370A1 (en) Treatment of Cancer with TOR Kinase Inhibitors
KR102122617B1 (ko) Tor 키나제 억제자를 사용하는 암의 치료
JP6470822B2 (ja) Torキナーゼ阻害剤を用いた癌の治療
EP2825168B1 (en) Treatment of cancer with tor kinase inhibitors
JP2013518890A (ja) Torキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのlkb1変異の同定
CN103998036A (zh) 利用tor激酶抑制剂治疗癌症
AU2015213400B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2015201138B2 (en) Treatment of cancer with TOR kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1201753B (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210607

Application number text: 1020207016306

Filing date: 20200605

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210629

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220616

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210629

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I